Bank of America’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Bank of America’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-142,074	Closed	-$1.4M	–	8654
2022 Q1	$1.4M	Hold	142,074	–	–	﹤0.01%	4921
2021 Q4	$1.39M	Buy	+142,074	New	+$1.39M	﹤0.01%	4935

Other funds holding EUCR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

ECU

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Bank of America's EUCR Position: Q2 2022 in Review

Bank of America sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2022, closing a stake of 142,074 shares — an estimated $1.4M sold.

Bank of America first reported a position in EUCR in Q4 2021 and held it in 2 quarters. The position peaked at $1.4M in Q1 2022. 37 funds tracked by Wall St. Rank hold EUCR as of Q2 2022.

Bank of America reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Bank of America sold 142,074 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2022, an estimated $1.4M.
Bank of America first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 2 quarters.
Bank of America's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $1.4M in Q1 2022.
37 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2022.

Based on Bank of America's 13F filing for Q2 2022, filed 12 Aug 2022.